Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.

Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Piña IL, O'Connor CM.

Circ Heart Fail. 2012 Jan;5(1):72-8. doi: 10.1161/CIRCHEARTFAILURE.111.963637. Epub 2011 Oct 20.

2.

Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.

Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Piña IL, Zannad F, Kraus WE, O'Connor CM.

Circ Heart Fail. 2013 Nov;6(6):1172-9. doi: 10.1161/CIRCHEARTFAILURE.113.000207. Epub 2013 Oct 8.

3.

Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.

Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, Donahue MP, Kraus WE, Piña IL, Whellan DJ, O'Connor CM.

J Card Fail. 2014 Jan;20(1):38-44. doi: 10.1016/j.cardfail.2013.11.011. Epub 2013 Dec 1.

4.

Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.

Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F.

Arch Cardiovasc Dis. 2013 Oct;106(10):541-6. doi: 10.1016/j.acvd.2013.06.054. Epub 2013 Oct 3.

5.

Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model.

O'Connor CM, Whellan DJ, Wojdyla D, Leifer E, Clare RM, Ellis SJ, Fine LJ, Fleg JL, Zannad F, Keteyian SJ, Kitzman DW, Kraus WE, Rendall D, Piña IL, Cooper LS, Fiuzat M, Lee KL.

Circ Heart Fail. 2012 Jan;5(1):63-71. doi: 10.1161/CIRCHEARTFAILURE.111.963462. Epub 2011 Nov 23.

6.

Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.

Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P.

Clin Res Cardiol. 2013 Feb;102(2):103-10. doi: 10.1007/s00392-012-0500-y. Epub 2012 Aug 12.

PMID:
22886030
7.

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA.

Circ Heart Fail. 2013 Mar;6(2):219-26. doi: 10.1161/CIRCHEARTFAILURE.112.000129. Epub 2013 Feb 8.

8.

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM.

J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24. Epub 2006 Aug 28.

9.

Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials.

Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA.

Am Heart J. 2014 Jun;167(6):853-60.e4. doi: 10.1016/j.ahj.2014.02.011. Epub 2014 Mar 5.

10.

Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.

Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL.

Eur J Heart Fail. 2013 Oct;15(10):1157-63. doi: 10.1093/eurjhf/hft075. Epub 2013 May 10.

11.

Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Piña IL, Adams KF, Kitzman DW, O'Connor CM, Felker GM.

JACC Heart Fail. 2014 Jun;2(3):260-8. doi: 10.1016/j.jchf.2013.12.004.

12.

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.

Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J; CORONA Study Group.

Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. Epub 2013 Nov 27.

13.

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.

Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P.

Eur J Heart Fail. 2012 Jan;14(1):74-81. doi: 10.1093/eurjhf/hfr151. Epub 2011 Nov 16.

14.

Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.

von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.

J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. Epub 2007 Oct 29.

15.

Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.

Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE.

Circ Heart Fail. 2011 Sep;4(5):569-77. doi: 10.1161/CIRCHEARTFAILURE.111.962654. Epub 2011 Jun 29.

16.

Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction.

Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Páez-Rubio MI, Arias-Jiménez JL, Aguayo-Canela M, Pérez-Calvo JI.

Int J Cardiol. 2013 Nov 5;169(3):177-82. doi: 10.1016/j.ijcard.2013.08.081. Epub 2013 Sep 7.

PMID:
24207066
17.

Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.

Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Peter M, Pfisterer MP, Brunner-La Rocca HP; TIME-CHF Investigators.

Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18.

18.

The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure.

Zhang Y, Zhang R, An T, Huang Y, Guo X, Yin S, Wang Y, Ji S, Lv R, Zhang J, Maisel A.

J Card Fail. 2015 Jan;21(1):51-9. doi: 10.1016/j.cardfail.2014.10.006. Epub 2014 Oct 16.

PMID:
25463412
19.

Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure.

Ahmad T, O'Brien EC, Schulte PJ, Stevens SR, Fiuzat M, Kitzman DW, Adams KF, Kraus WE, Piña IL, Donahue MP, Zannad F, Whellan DJ, O'Connor CM, Felker GM.

Circ Heart Fail. 2015 Jul;8(4):709-16. doi: 10.1161/CIRCHEARTFAILURE.114.001996. Epub 2015 Jun 1.

PMID:
26034004
20.

Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure.

Yu X, Sun Y, Zhao Y, Zhang W, Yang Z, Gao Y, Cai H, Li Y, Wang Q, Bian B, Nie J.

Int Heart J. 2015 May 13;56(3):314-8. doi: 10.1536/ihj.14-304. Epub 2015 Apr 23.

Items per page

Supplemental Content

Write to the Help Desk